Dianthus Therapeutics, Inc.
DNTH
$16.86
-$0.585-3.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.77% | -12.97% | -42.98% | -28.07% | -30.15% |
| Total Depreciation and Amortization | 70.51% | -73.01% | 566.13% | -157.94% | 3.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 154.55% | 31.50% | -64.27% | 88.00% | 662.31% |
| Change in Net Operating Assets | -294.08% | -116.24% | 799.31% | 110.26% | -76.84% |
| Cash from Operations | -0.68% | -29.04% | -46.39% | 2.76% | -26.04% |
| Capital Expenditure | 22.58% | -24.00% | -47.06% | 46.88% | -220.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 164.21% | 91.10% | -21,966.69% | 121.66% | 33.45% |
| Cash from Investing | 164.02% | 91.09% | -22,286.83% | 121.23% | 33.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.59% | 13,304.05% | 529.79% | -99.98% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 81.94% | -155.33% |
| Cash from Financing | -99.59% | 13,304.05% | 113.48% | -101.01% | 4,577.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.52% | 96.12% | -1,702.22% | -107.88% | 890.99% |